Sangui Bio develops blood-based proteomic diagnostics that detect disease biomarkers from a fingerprick sample collected at home. Founded in 2015, the company operates from the Kolling Institute at Royal North Shore Hospital in Sydney.
Sangui Bio was founded to commercialise discoveries that changed the way blood is analysed for disease biomarkers. Our work established that dried whole blood contains deep proteomic information that conventional plasma analysis discards.
From this foundation, the company built VeriPro, a whole-blood proteomics platform that quantifies approximately 4,000 proteins from a single 30 µL fingerprick sample. The first application is ColoPro, a blood test for early detection of colorectal cancer.
VeriPro combines at-home patient-centric microsampling with LC-MS/MS mass spectrometry and machine learning. proprietary sequential extraction enables the detection and quantification of approximately 4,000 proteins from a single 30 µL dried blood spot.
The platform also supports PCR quantification of circulating tumour DNA (ctDNA) mutants such as EGFR and KRAS from the same samples, enabling multi-analyte analysis from one collection event.
Explore ColoPro →
Sangui Bio is based at the Kolling Institute, a partnership between the Northern Sydney Local Health District and the University of Sydney. Located at Royal North Shore Hospital, the company has direct access to clinical trial capacity, a network of clinicians and researchers, and world-class research infrastructure.
Our Clinical Network →Discovery-mode mass spectrometry covering thousands of proteins per sample, optimised for the unique chemistry of dried whole blood.
Proprietary sequential extraction methods that separate intracellular, membrane and cytokine fractions from a single dried blood spot.
Embedded in the Northern Sydney Local Health District tertiary network, with established ethics and regulatory infrastructure.
DIA mass spectrometry quantifying ~4,000 proteins from 30 µL of dried blood, well beyond the reach of conventional plasma analysis.
At-home patient-centric microsampling that supports repeat testing across surveillance windows and clinical trials.
A platform built for population-scale deployment: postable sample collection, automated extraction, and centralised LDT processing.
Sangui Bio collaborates with gastroenterology practices, clinical research groups, and strategic partners. If you are interested in our work, we would like to hear from you.
Contact Sangui Bio →
